Literature DB >> 3950582

Neutralizing (54K) and non-neutralizing (54K and 48K) monoclonal antibodies against structural and non-structural yellow fever virus proteins confer immunity in mice.

E A Gould, A Buckley, A D Barrett, N Cammack.   

Abstract

The capacity of monoclonal antibodies to protect mice passively against yellow fever (YF) virus infection was investigated. Both neutralizing (54K-specific) and non-neutralizing (54K- and 48K-specific) antibodies protected mice against challenge with the RMP substrain of YF virus. Average survival times of mice inoculated intracerebrally with a standard lethal dose of YF virus differed according to the strain used: thus mice inoculated with the most neurovirulent viruses, FNV and Asibi, survived for 6 X 50 and 7 X 65 days respectively, and those with RMP virus survived for 15 X 75 days. The capacity of antibodies to protect mice passively against virus challenge was directly related to virus neurovirulence. Possible mechanisms and the significance of protection by antibodies against non-structural proteins that do not mediate neutralization, are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3950582     DOI: 10.1099/0022-1317-67-3-591

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  43 in total

1.  Characterization of a siberian virus isolated from a patient with progressive chronic tick-borne encephalitis.

Authors:  T S Gritsun; T V Frolova; A I Zhankov; M Armesto; S L Turner; M P Frolova; V V Pogodina; V A Lashkevich; E A Gould
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus.

Authors:  A V Timofeev; V M Butenko; J R Stephenson
Journal:  Virus Genes       Date:  2004-01       Impact factor: 2.332

3.  A short N-terminal peptide motif on flavivirus nonstructural protein NS1 modulates cellular targeting and immune recognition.

Authors:  Soonjeon Youn; Hyelim Cho; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

4.  Flavivirus nonstructural protein NS1: complementary surprises.

Authors:  Jacob J Schlesinger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-04       Impact factor: 11.205

5.  Expression of the NS1 gene of dengue virus type 2 using vaccinia virus. Dimerisation of the NS1 glycoprotein.

Authors:  C R Parrish; W S Woo; P J Wright
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

6.  Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms.

Authors:  Kyung Min Chung; Grant E Nybakken; Bruce S Thompson; Michael J Engle; Anantha Marri; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

7.  Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model.

Authors:  Justin G Julander; Dennis W Trent; Thomas P Monath
Journal:  Vaccine       Date:  2011-06-28       Impact factor: 3.641

8.  Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation.

Authors:  I R Muylaert; R Galler; C M Rice
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

9.  Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus.

Authors:  Ruhe Men; Tetsu Yamashiro; Ana P Goncalvez; Claire Wernly; Darren J Schofield; Suzanne U Emerson; Robert H Purcell; Ching-Juh Lai
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Authors:  Bimmi Shrestha; James D Brien; Soila Sukupolvi-Petty; S Kyle Austin; Melissa A Edeling; Taekyung Kim; Katie M O'Brien; Christopher A Nelson; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.